OXFDinactive

OXFORD IMMUNOTEC GLOBAL PLC

Healthcare·Oncology·Commercial
OncologyNeurologyCardiovascularInfectious DiseaseHematologyPsychiatry

OXFORD IMMUNOTEC GLOBAL PLC (OXFD): 10 pipeline candidates · ~141 mo cash runway. Updated within the last hour.

10.0/10

BioSniper Score

4-factor signal · derived from public data

Cash Runway10.0

140.7 months

Financial Health9.8

D/E 0.10 · 0% dilution

Pipeline Maturity10.0

Lead: Approved

Pipeline Breadth10.0

10 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for OXFORD IMMUNOTEC GLOBAL PLCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

—

Cash

$160.6M

Quarterly Burn

$3.6M

Runway

140.7 mo

Revenue

$19.4M

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Mar 2038
Today~155 mo out
Catalyst within runway

Pipeline (10 candidates)

DrugPhase
amlodipineApproved
buspironeApproved
c6 lyme elisa kitApproved
dipyridamoleApproved
imipramineApproved
paroxetineApproved
spironolactoneApproved
t-spot.cmvApproved
t-spot.tbApproved
t-spot.tb testApproved
·1 FDA decision·CEO: Peter Wrighton

Frequently asked questions

How many drug candidates are in OXFORD IMMUNOTEC GLOBAL PLC's pipeline?

OXFORD IMMUNOTEC GLOBAL PLC (OXFD) has 10 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is OXFORD IMMUNOTEC GLOBAL PLC's lead drug candidate?

OXFORD IMMUNOTEC GLOBAL PLC's most advanced tracked candidate is amlodipine (Approved) for 1 INDICATIONS AND USAGE Amlodipine besylate tablets are a calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of: Hypertension ( 1.1 ) Amlodipine besylate tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Coronary Artery Disease ( 1.2 ) Chronic Stable Ang.

What is OXFORD IMMUNOTEC GLOBAL PLC's cash runway?

Based on its most recent reported cash balance and quarterly burn rate, OXFORD IMMUNOTEC GLOBAL PLC has approximately 140.7 months of cash runway.

Who is the CEO of OXFORD IMMUNOTEC GLOBAL PLC?

Peter Wrighton is the chief executive officer of OXFORD IMMUNOTEC GLOBAL PLC (OXFD).

Get the full picture on OXFORD IMMUNOTEC GLOBAL PLC

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.

Start Free AnalysisBrowse Calendar